A recent study published in the August issue of the American Journal of Cardiology shows that a one-year consumption of a grape nutraceutical containing resveratrol may improve the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease.
Grape and wine polyphenol resveratrol confers cardiovascular benefits, in part by exerting anti-inflammatory effects. However, the evidence in human long-term clinical trials has yet to be established. This latest study aimed to investigate the effects of a dietary resveratrol-rich grape supplement on the inflammatory and fibrinolytic status of subjects at high risk of cardiovascular disease (CVD) and treated according to current guidelines for primary prevention of CVD.
Seventy-five patients undergoing primary prevention of CVD participated in this triple-blinded, randomized, parallel, dose–response, placebo-controlled, 1-year follow-up trial. Patients, allocated in 3 groups, consumed placebo (maltodextrin), a resveratrol-rich grape supplement (resveratrol 8 mg), or a conventional grape supplement lacking resveratrol, for the first 6 months and a double dose for the next 6 months.
In contrast to placebo and conventional grape supplement, the resveratrol-rich grape supplement significantly improved the health condition of patients who were on statins for primary prevention of CVD and at high CVD risk. No adverse effects were observed in any patient.